亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study

吡非尼酮 任天堂 医学 耐受性 特发性肺纤维化 中止 不利影响 内科学 胃肠病学 肺
作者
Ruiming Zhao,Bingbing Xie,Xin Wang,Xinran Zhang,Yanhong Ren,Chen Wang,Huaping Dai
出处
期刊:Pulmonary Pharmacology & Therapeutics [Elsevier BV]
卷期号:84: 102287-102287 被引量:22
标识
DOI:10.1016/j.pupt.2024.102287
摘要

Abstract Background:Idiopathic pulmonary fibrosis is a progressive and fatal lung disease that lacking effective therapeutics. Treatment with pirfenidone or nintedanib is recommended for patients to delay the progression of the disease. Anti-fibrosis drugs may cause adverse reactions, even interrupt the treatment, affecting the disease's progress. Objective:To investigation the current situation and adverse reactions of using pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Methods: We recruited patients with idiopathic pulmonary fibrosis who were treated with pirfenidone or nintedanib in China-Japan Friendship Hospital from February 2017 to February 2022. Conduct an investigation of the medication situation, adverse reactions and survival of patients while taking medications. Results: A total of 303 patients with idiopathic pulmonary fibrosis were enrolled in the study, including 205 patients received pirfenidone and 98 patients received nintedanib. Baseline data between the two groups were not significantly different. Patients treated with nintedanib had a higher overall discontinuation rate than those treated with pirfenidone (61.22 vs 32.68%, P<0.001). The primary reason of patients discontinued treatment across all patient groups is medication-related adverse effects. Compared to pirfenidone, nintedanib had a significantly higher rate of treatment discontinuation due to adverse events (48.98% vs 27.80%, P<0.001). Both drugs have digestive system side effects, diarrhea is the most common. Pirfenidone was associated with a higher rate of extra-digestive adverse effects than nintedanib. Survival was not significantly different between the two drugs, and the use of pirfenidone above 1200 mg/day did not confer significant survival benefits. Conclusion: Gastrointestinal adverse effects are the main adverse effects that arise from performing antifibrotic therapy. Patients taking nintedanib were more likely to interrupt their treatment due to gastrointestinal side effects, while patients taking pirfenidone had more extra gastrointestinal side effects. It is possible that patients might benefit from modifying dosages of antifibrotic drugs according to their own tolerance, but taking more than 1200 mg/day of pirfenidone did not seem to produce any significant improvements in patient survival time.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小蘑菇的应助被sue采纳,获得10
2秒前
大橙子完成签到 ,获得积分10
3秒前
5秒前
8秒前
8秒前
ZT1发布了新的文献求助10
9秒前
wejcxl完成签到,获得积分10
11秒前
ubless607发布了新的文献求助50
13秒前
李健的应助被萧雨墨采纳,获得10
13秒前
初初初啊发布了新的文献求助10
14秒前
cjy完成签到 ,获得积分10
16秒前
17秒前
cccc完成签到,获得积分10
18秒前
温良完成签到 ,获得积分10
20秒前
21秒前
22秒前
初初初啊发布了新的文献求助10
23秒前
科研通AI6.4的应助被香果采纳,获得10
23秒前
突突完成签到 ,获得积分10
24秒前
25秒前
26秒前
26秒前
sue发布了新的文献求助10
28秒前
29秒前
29秒前
无语的幻露完成签到,获得积分10
29秒前
初初初啊发布了新的文献求助10
31秒前
萧雨墨发布了新的文献求助10
32秒前
32秒前
千早爱音完成签到 ,获得积分10
32秒前
DTS发布了新的文献求助10
33秒前
34秒前
34秒前
抚琴祛魅完成签到 ,获得积分10
35秒前
40秒前
何在完成签到,获得积分10
41秒前
Lucas的应助被DTS采纳,获得10
42秒前
44秒前
Ziezer完成签到,获得积分10
45秒前
初初初啊发布了新的文献求助10
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851884
捐赠科研通 7788155
什么是DOI,文献DOI怎么找? 3436233
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792